B-(9,9-Diphenyl-9H-fluoren-4-yl)boronic acid | CAS:1224976-40-2

We serve B-(9,9-Diphenyl-9H-fluoren-4-yl)boronic acid CAS:1224976-40-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
B-(9,9-Diphenyl-9H-fluoren-4-yl)boronic acid

Chemical Name:B-(9,9-Diphenyl-9H-fluoren-4-yl)boronic acid
CAS.NO:1224976-40-2
Synonyms:Boronic acid,B-(9,9-diphenyl-9H-fluoren-4-yl)-
4-Boronic acid-9,9'-diphenylfluorene
4-BADPF
B-(9,9-Diphenyl-9H-fluoren-4-yl)boronic acid
9,9-Diphenyl-9H-fluorene-4-boronic Acid
Molecular Formula:C25H19BO2
Molecular Weight:362.22800
 
Specification:
Appearance:Off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like B-(9,9-Diphenyl-9H-fluoren-4-yl)boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,9,9-Diphenyl-9H-fluorene-4-boronic Acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Boronic acid,B-(9,9-diphenyl-9H-fluoren-4-yl)- Use and application,B-(9,9-Diphenyl-9H-fluoren-4-yl)boronic acid technical grade,usp/ep/jp grade.


Related News: Our previous work with Retrogenix validated their technology as a uniquely powerful approach for antibody target deconvolution, and we look forward to working with Retrogenix to enhance our growing pipeline of antibody candidates.”(9-phenylcarbazol-2-yl)boronic acid manufacturer According to the business type, it can be divided into non-CMO business of APIs and intermediates and CMO business of APIs and intermediates.(R)-4-Hydroxy-N,N-diphenylpent-2-ynamide supplier Jo Soden, Co-managing Director of Retrogenix, said “We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant’s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”5-methyl-2'-deoxycytidine vendor ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.Zhejiang Tianyu Co., Ltd .: It is mainly engaged in the research and development and production of sartan-type APIs and intermediates. It has serialized sartan-type APIs and intermediate products, and has accumulated rich chemical synthesis technology. It has strong technical advantages and Scale advantage.